The Asia Pacific Neurological Biomarkers Market would witness market growth of 15.0% CAGR during the forecast period (2022-2028).
Neurofilament light (NFL), a biomarker for a neuronal injury that denotes head trauma, is one type of biomarker that Quanterix can evaluate in blood. A team led by Kaj Blennow and Henrik Zetterberg at the University of Gothenburg in Mölndal, Sweden, has discovered that college football players' levels of the biomarker NFL increased during a football season, but not in contact-free control athletes.
Hrusovsky hopes that parents and coaches will be able to evaluate the effects of athletes' head injuries without invasive testing on the sidelines of soccer or football games. He hopes that early detection and surveillance will stop the development of more complicated disorders like CTE. Another effective approach for researching neurological disorders and conditions is the identification of biomarker signatures using panels of high-quality antibodies.
The prevalence of neurological illnesses is a significant social and economic issue. They are the biggest cause of disability and the second leading cause of mortality. The incidence, prevalence, mortality, and impairment rates of neurological illnesses have increased internationally during the past 25 years despite the deployment of methods and intervention programs to lessen the burden, primarily due to population aging and growth.
An excess or deficiency of this energy, known as Vata, can cause the neurological system to become overactive or weak. Ayurvedic texts include more than 80 neurological disorders. Additionally, 2018 Parkinson's NSW, Monash University, and the University of Melbourne predicted that by 2034, there will be 212,000 Australians living with Parkinson's disease, a 79 percent increase in prevalence. The demand for neuromodulators is rising as neurological illnesses become more prevalent since they can treat neurological symptoms. These factors will speed up the development of the neurological biomarkers market in this region.
The China market dominated the Asia Pacific Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $1,010 Million by 2028. The Japan market is anticipated to grow at a CAGR of 14.3% during (2022 - 2028). Additionally, The India market would obtain a CAGR of 15.7% during (2022 - 2028).
Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Neurological Biomarkers Market is Projected to reach USD 12.9 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
By Type
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 